ZECUITY

Peak

sumatriptan succinate

NDAIONTOPHORESISSYSTEM
Approved
Jan 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
7

Clinical Trials (5)

NCT02684409Phase 1Completed

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine

Started Aug 2013
37 enrolled
Acute Migraine
NCT00875784Phase 1Completed

An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)

Started May 2008
30 enrolled
Migraine Disorders
NCT00382993Phase 3Completed

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

Started Dec 2006
169 enrolled
Migraine Disorders
NCT00383162Phase 3Completed

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)

Started Nov 2006
173 enrolled
Migraine Disorders
NCT00356603Phase 3Completed

Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan

Started Jun 2006
75 enrolled
Migraine Disorders

Loss of Exclusivity

LOE Date
Oct 8, 2032
80 months away
Patent Expiry
Oct 8, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
9427578
Apr 12, 2027
Product
U-1328
8155737
Apr 12, 2027
U-1328
8470853
Apr 12, 2027
U-1328
8597272
Apr 12, 2027
Product
7973058
Apr 12, 2027
U-1328